Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer
NCT00095277
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
220
Enrollment
INDUSTRY
Sponsor class
Conditions
Anemia
Interventions
DRUG:
Darbepoetin Alfa
Sponsor
Amgen